Femasys Inc. Accretion Expense
Femasys Inc. (FEMY) reported Accretion Expense of $132.14 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2026-03-31
- Femasys Inc. accretion expense for fiscal 2025 was $132.14K.
- Femasys Inc. accretion expense for fiscal 2024 was $0.00.
| Period end | Accretion Expense 12 month |
|---|---|
| 2025-12-31 | $132.14K 10-K · filed 2026-03-31 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RETRACTABLE TECHNOLOGIES INC (RVP) | United States | $0.021B | -6.44 |
| HeartBeam, Inc. (BEAT) | United States | $0.022B | -2.08 |
| Modular Medical, Inc. (MODD) | United States | $0.018B | -0.88 |
| SeaStar Medical Holding Corp (ICU) | United States | $0.015B | -1.14 |
| CERENOME, INC. (CNSY) | United States | $0.014B | |
| ACCURAY INC (ARAY) | United States | $0.027B | -0.63 |
| Glucotrack, Inc. (GCTK) | United States | $0.027B | |
| Sintx Technologies, Inc. (SINT) | United States | $0.012B | -1.10 |
| NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) | United States | $0.012B | |
| Picard Medical, Inc. (PMI) | United States | $0.011B | -0.01 |